Key points are not available for this paper at this time.
Objectives: Selenium deficiency in patients with gastrointestinal diseases treated with long-term central venous nutrition is a clinical problem. Only injectable selenium is approved in Japan, and oral selenium preparations are prepared in hospitals from reagents, but their efficacy and safety are unknown. Methods: We conducted a retrospective study investigating the relationship between selenium administration and oral selenium formulations and adverse events. Results: In this study, 239 selenium-treated cases and 220 selenium-untreated cases adjusted for patient background were selected as a reference group. The median (interquartile range, IQR) age was 1.3 (0.4–4.4) and 1.3 (0.3–4.5) years, respectively; gastrointestinal diseases were most common in 110 (46.0%) and 104 (47.3%) cases. The median (IQR) duration of treatment or observation with oral selenium was 446 (128–1157) and 414 (141–1064) days, respectively. The median (IQR) dose per body weight at the maintenance dose was 2.6 (1.7–3.9) μg/kg, and the median (IQR) serum selenium concentration at the maintenance dose was 8.5 (7.0–10.6) μg/mL within the upper tolerated dose limit and approximately the reference range. There was no difference in selenium dose, serum selenium concentration, or serum-selenium-concentration-to-dose ratio (C/D ratio) for adverse events. The incidence of adverse events was compared with that of patients not treated with selenium. Conclusions: An oral selenium preparation administered below the upper tolerated dose limit can be used effectively and safely in pediatric patients.
Saito et al. (Tue,) studied this question.